InMode’s Aesthetic Platform Sees Triple-Digit Growth
September 14, 2022
Trending News ☀️
INMODE($NASDAQ:INMD): InMode’s minimally-invasive products had triple-digit top-line growth in FY21. The robust demand was driven by the functional differentiation from InMode’s proprietary platform, also called paradigm 2 of the aesthetic evolution. InMode’s technology is clinically proven to provide superior results with less downtime and fewer side effects. InMode is well-positioned to continue its strong growth in the aesthetic market.
Market Price
InMode, a medical technology company, saw its stock prices go down by 2.5% on Tuesday, with its stock opening at $31.7 and closing at $32.8. This is in contrast to its previous closing price of $33.6. InMode is committed to providing the best possible results for its patients, and its products are backed by years of research and development.
VI Analysis
INMODE’s fundamentals reflect its long term potential according to the VI app. INMODE is strong in asset, growth, profitability, and weak in dividend according to the VI Star Chart. INMODE is classified as ‘gorilla’, a type of company that achieved stable and high revenue or earning growth due to its strong competitive advantage. High growth companies are deemed more risky as they attempt to grow faster. INMODE has a high health score of 8/10 considering its cashflows and debt, is capable to pay off debt and fund future operations.
Summary
The company’s innovative technology has made it a leader in the industry, and its strong financials back up its impressive growth. InMode is a great long-term investment for those looking to profit from the continued growth of the aesthetic market.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
